• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期肝硬化肝细胞癌肝移植的选择标准:一项多中心研究结果

Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study.

作者信息

Figueras J, Ibañez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, Mir J, Loinaz C, Herrera L, López-Cillero P, Santoyo J

机构信息

Ciudad Sanitaria y Universitaria (CSU) Bellvitge, Barcelona, Spain.

出版信息

Liver Transpl. 2001 Oct;7(10):877-83. doi: 10.1053/jlts.2001.27856.

DOI:10.1053/jlts.2001.27856
PMID:11679986
Abstract

Orthotopic liver transplantation (OLT) offers the only chance to eliminate both tumor and liver disease in patients with hepatocellular carcinoma (HCC) and cirrhosis. However, tumor progression while on the waiting list and recurrence after OLT are frequent. We undertook a large multicenter study to assess survival and related factors of recurrence after OLT. This retrospective study analyses data from 307 consecutive patients with HCC and cirrhosis treated with OLT between 1990 and 1997 in eight centers in Spain. OLT was indicated only for small (<5 cm) localized tumors. Five-year rates after OLT were 63% for survival, 58% for disease-free survival, and 21% for recurrence. Tumor diameter larger than 5 cm was associated with other tumor characteristics that were significant indicators of poor outcome (absence of capsule, three or more nodules, bilobularity, satellite nodules, and vascular invasion). However, in multivariate analysis, alpha fetoprotein (AFP) levels greater than 300 ng/mL (P = .04; P = .02) and macroscopic vascular invasion (P = .01; P = .0001) were the only factors independently associated with mortality and recurrence, respectively. OLT is indicated in patients with small HCCs who have low AFP levels and no macroscopic vascular invasion or extrahepatic disease. By increasing our ability for preoperative tumor imaging, we will achieve better selection of patients with HCC before OLT.

摘要

原位肝移植(OLT)为消除肝细胞癌(HCC)合并肝硬化患者的肿瘤和肝脏疾病提供了唯一机会。然而,等待移植期间肿瘤进展以及OLT后复发的情况很常见。我们开展了一项大型多中心研究,以评估OLT后患者的生存率及复发相关因素。这项回顾性研究分析了1990年至1997年间西班牙八个中心连续接受OLT治疗的307例HCC合并肝硬化患者的数据。OLT仅适用于小(<5 cm)局限性肿瘤。OLT后的五年生存率为63%,无病生存率为58%,复发率为21%。肿瘤直径大于5 cm与其他肿瘤特征相关,这些特征是预后不良的重要指标(无包膜、三个或更多结节、双叶性、卫星结节和血管侵犯)。然而,在多变量分析中,甲胎蛋白(AFP)水平大于300 ng/mL(P = .04;P = .02)和肉眼可见的血管侵犯(P = .01;P = .0001)分别是与死亡率和复发独立相关的唯一因素。OLT适用于AFP水平低且无肉眼可见血管侵犯或肝外疾病的小HCC患者。通过提高我们术前肿瘤成像的能力,我们将在OLT前更好地选择HCC患者。

相似文献

1
Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study.早期肝硬化肝细胞癌肝移植的选择标准:一项多中心研究结果
Liver Transpl. 2001 Oct;7(10):877-83. doi: 10.1053/jlts.2001.27856.
2
Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study.肝硬化合并和不合并肝细胞癌患者肝移植后的生存率:一项对比研究。
Hepatology. 1997 Jun;25(6):1485-9. doi: 10.1002/hep.510250629.
3
Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.早期肝细胞癌的肝移植结局:一项多中心研究的结果
Liver Transpl. 2004 Nov;10(11):1343-54. doi: 10.1002/lt.20311.
4
Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.丙型肝炎相关肝细胞癌肝移植术后生存的预测因素
Liver Transpl. 2004 Dec;10(12):1478-86. doi: 10.1002/lt.20303.
5
Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.肝细胞癌肝移植术后长期生存的预测因素。
Am J Gastroenterol. 2005 Dec;100(12):2708-16. doi: 10.1111/j.1572-0241.2005.00289.x.
6
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.肝细胞癌肝移植:当前选择标准对预后预测的验证
Liver Transpl. 2004 Jul;10(7):911-8. doi: 10.1002/lt.20140.
7
Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma.肝硬化合并肝细胞癌患者肝移植的扩大标准
Liver Transpl. 2008 Oct;14(10):1449-60. doi: 10.1002/lt.21576.
8
Undetected hepatocellular carcinoma in patients undergoing liver transplantation: is associated with favorable outcome.肝移植患者中未被检测到的肝细胞癌:与良好预后相关。
Hepatogastroenterology. 2007 Jun;54(76):1192-5.
9
Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.肝细胞癌患者在等待肝移植期间先进行化疗栓塞可延缓肿瘤进展,并带来良好的预后。
Liver Transpl. 2003 Jun;9(6):557-63. doi: 10.1053/jlts.2003.50106.
10
Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.米兰标准以外的肝细胞癌的外科治疗。肝切除、挽救性移植和原位肝移植的结果。
Ann Surg Oncol. 2008 May;15(5):1383-91. doi: 10.1245/s10434-008-9851-z. Epub 2008 Mar 5.

引用本文的文献

1
Percutaneous vacuum-assisted tumor thrombectomy using angiovac and penumbra lightning 12 aspiration systems.使用Angiovac和Penumbra Lightning 12抽吸系统进行经皮真空辅助肿瘤血栓切除术。
Radiol Case Rep. 2025 Feb 4;20(4):2194-2202. doi: 10.1016/j.radcr.2025.01.058. eCollection 2025 Apr.
2
Breaking down tumor thrombus: Current strategies for medical management.肿瘤栓子的破解:目前的医学治疗策略。
Thromb Res. 2023 Oct;230:144-151. doi: 10.1016/j.thromres.2023.09.004. Epub 2023 Sep 13.
3
High pre-treatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma.
治疗前较高的静态和动态甲胎蛋白值预示着肝细胞癌患者总生存期缩短。
United European Gastroenterol J. 2020 Nov 23;9(3):2050640620972611. doi: 10.1177/2050640620972611.
4
Predicting tumor recurrence using metabolic indices of F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma.在原位肝移植治疗肝细胞癌之前,利用F-FDG PET/CT的代谢指标预测肿瘤复发
Oncol Lett. 2020 Aug;20(2):1245-1255. doi: 10.3892/ol.2020.11681. Epub 2020 May 28.
5
Thrombolysis in Postoperative Pulmonary Embolism Following Liver Transplantation: A Case Report.肝移植术后肺栓塞的溶栓治疗:一例报告
Am J Case Rep. 2020 Feb 18;21:e918857. doi: 10.12659/AJCR.918857.
6
Tumor thrombus: incidence, imaging, prognosis and treatment.肿瘤血栓:发病率、影像学、预后及治疗
Cardiovasc Diagn Ther. 2017 Dec;7(Suppl 3):S165-S177. doi: 10.21037/cdt.2017.09.16.
7
Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.甲胎蛋白水平可预测肝细胞癌移植后的复发情况。
Medicine (Baltimore). 2016 Jan;95(3):e2478. doi: 10.1097/MD.0000000000002478.
8
Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.肝细胞癌患者肝移植的选择:过去与未来
World J Hepatol. 2016 Jan 8;8(1):58-68. doi: 10.4254/wjh.v8.i1.58.
9
Long-term outcome after liver resection and clinicopathological features in patients with small hepatocellular carcinoma.小肝细胞癌患者肝切除术后的长期预后及临床病理特征
Korean J Hepatobiliary Pancreat Surg. 2011 Nov;15(4):199-205. doi: 10.14701/kjhbps.2011.15.4.199. Epub 2011 Dec 15.
10
Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway.干扰素-γ诱导蛋白10(IP10)通过内质网应激信号通路诱导肝移植后肝癌的顺铂耐药。
Oncotarget. 2015 Sep 29;6(29):28042-56. doi: 10.18632/oncotarget.4832.